For Instant Free Demat Account Call : +91 9559411441
Email : info@smartmoneygrow.com
For Instant Free Demat Account Call : +91 9559411441
Email : info@smartmoneygrow.com
As Zenith Drugs Limited launches its Initial Public Offering (IPO) from February 19 to February 22, 2024, this blog post delves into the key details and insights surrounding this pharmaceutical venture. From the IPO timeline to financial performance and the company’s objectives, readers will gain a thorough understanding of Zenith Drugs Limited’s potential in the market.Zenith Drugs IPO is expected to be finalized on Friday, February 23, 2024. Zenith Drugs IPO will list on NSE SME with tentative listing date fixed as Tuesday, February 27, 2024
IPO Details:
Unveiling the specifics of the IPO, with a fresh issue of 51.49 lakh shares totaling Rs 40.68 crores.
Subscription period from February 19 to February 22, 2024, and the expected allotment on February 23, 2024.
Anticipated listing on NSE SME by February 27, 2024.
Pricing and Lot Size:
The IPO price band set at ₹75 to ₹79 per share.
Retail investors required a minimum investment of ₹126,400 for 1600 shares, while HNIs had a minimum lot size of 3200 shares, amounting to ₹252,800.
Company Profile:
A brief history of Zenith Drugs Limited since its incorporation in 2000.
Specialization in manufacturing and trading high-quality, affordable medicines, with adherence to WHO-GMP guidelines.
Overview of their diverse product portfolio, global presence, and third-party manufacturing collaborations.
Financial Performance:
Highlighting the company’s financial growth with a 24.85% revenue increase and a 64.7% rise in profit after tax between March 2022 and March 2023.
Key financial indicators such as assets, net worth, and reserves and surplus.
Key Performance Indicators (KPIs):
Analyzing critical KPIs like Return on Equity (ROE), Return on Capital Employed (ROCE), Debt/Equity ratio, Return on Net Worth (RoNW), and Price-to-Book Value (P/BV).
Comparing pre-IPO and post-IPO metrics, including Earnings Per Share (EPS) and Price-to-Earnings (P/E) ratios.
smartmoneygrow.com © 2020 | All Rights Reserved
